MedTrace Logo

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

NCT02626182 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-07-24

Study results available
· View outcomes & findings →

Summary

This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.

Conditions

Interventions

DRUG

sildenafil

active sildenafil

DRUG

placebo

sugar pill that looks like sildenafil tablets

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Jennifer L Taylor-Cousar, MD · National Jewish Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-01-18
Completion
2018-01-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626182 on ClinicalTrials.gov